Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of IW-1973 in Healthy Volunteers
NCT02616861Phase 1Completed
- Sponsor
- Cyclerion Therapeutics
- Start
- Nov 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and diabetic kidney disease (DKD) comparing IW-1973 with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events at 42 Days, Maximum observed plasma concentration at 42 Days and 5 more. Started Nov 2015; status: completed.
02
Drugs
praliciguat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT02616861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02616861.